Evidence map›Paper›PMID 31559379›Full record

ArticleJournal of pancreatic cancer2019

A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus

Vaibhav Sahai, M Wasif Saif, Aparna Kalyan, Philip A Philip, Caio M Rocha-Lima, Allyson Ocean, Michael S Ondovik, Diane M Simeone, Sibabrata Banerjee, Rafia Bhore and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pancreatic cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Clinical immunotherapy in pancreatic cancer.Cancer immunology, immunotherapy : CII · 2024
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Vaibhav SahaiDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
M Wasif SaifMedical Oncology, Northwell Health Cancer Institute, Lake Success, New York.
Aparna KalyanDepartment of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Philip A PhilipDepartment of Oncology, Karmanos Cancer Institute, Detroit, Michigan.
Caio M Rocha-LimaDepartment of Oncology, Wake Forest School of Medicine, Bowman Gray Center, Winston-Salem, North Carolina.
Allyson OceanDepartment of Medical Oncology, Weill Cornell Medicine, New York, New York.
Michael S OndovikDepartment of Medical Affairs, Celgene Corporation, Summit, New Jersey.
Diane M SimeoneDepartment of General Surgery, NYU Langone Perlmutter Cancer Center, New York, New York.
Sibabrata BanerjeeDepartment of Medical Affairs, Celgene Corporation, Summit, New Jersey.
Rafia BhoreDepartment of Medical Affairs, Celgene Corporation, Summit, New Jersey.
Chrystal U LouisDepartment of Medical Affairs, Celgene Corporation, Summit, New Jersey.
Vincent PicozziDepartment of Oncology, Virginia Mason Medical Center, Seattle, Washington.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

5-fluorouracilcombination chemotherapymetastatic pancreatic cancernab-paclitaxel

Identifiers

PMID31559379
PMCPMC6761587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.